Logo Logo

Publications by Anthoney, Alan

Up a level
Export as [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date
Number of items: 2.

Journal article

Elander, N. O.; Aughton, K.; Ghaneh, P.; Neoptolemos, J. P.; Palmer, D. H.; Cox, T. F.; Campbell, F.; Costello, E.; Halloran, C. M.; Mackey, J. R.; Scarfe, A. G.; Valle, J. W.; McDonald, A. C.; Carter, R.; Tebbutt, N. C.; Goldstein, D.; Shannon, J.; Dervenis, C.; Glimelius, B.; Deakin, M.; Charnley, R. M.; Anthoney, Alan; Lerch, M. M.; Mayerle, J.; Olah, A.; Büchler, M. W.; Greenhalf, W. (2018): Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. In: British Journal of Cancer, Vol. 118, No. 7: pp. 947-954

Schoffski, Patrick; Wozniak, Agnieszka; Escudier, Bernard; Rutkowski, Piotr; Anthoney, Alan; Bauer, Sebastian; Sufliarsky, Jozef; Herpen, Carla van; Lindner, Lars H.; Grünwald, Viktor; Zakotnik, Branko; Lerut, Evelyne; Debiec-Rychter, Maria; Marreaud, Sandrine; Lia, Michela; Raveloarivahy, Tiana; Collette, Sandra; Albiges, Laurence (2017): Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial. In: European Journal of Cancer, Vol. 87: pp. 147-163

This list was generated on Tue Oct 15 06:24:20 2019 CEST.